Several studies have reported pathological coagulation parameters and platelet abnormalities in patients treated with various antiseizure drugs (ASDs), especially for Valproic acid (VPA) [1,2,3,4,5,6]. However, there is uncertainty whether these abnormalities result in a clinically relevant bleeding risk [2,7]. Studies on patients undergoing epilepsy surgery [1,4] have observed coagulopathies and platelet abnormalities, which have even led to the practice of stopping treatment with VPA before elective surgery in many centers [8], although this practice is discussed controversially in the literature [9].
10
MAY
MAY
0